Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. حسب Cathryn S. D. Maienza (20629929)

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. حسب Xiaoqin Li (1399105)

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. حسب Mingee Choi (15250732)

الموضوعات:

Treatment at first diagnosis of insomnia disorder (%). حسب Mingee Choi (15250732)

الموضوعات:

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. حسب Mingee Choi (15250732)

الموضوعات:

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). حسب Mingee Choi (15250732)

الموضوعات:

Transepithelial resistance of NHBE decreases significantly after PAA exposure. حسب Ellie S. Burns (21246537)

Brain regions with significantly decreased activations for the Raven task are shown in blue. حسب Morteza Fattahi (15892028)

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. حسب Mingee Choi (15250732)

الموضوعات:

Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... حسب Mingee Choi (15250732)

الموضوعات:

General information of patient who diagnosis insomnia disorder (N = 518,119). حسب Mingee Choi (15250732)

الموضوعات:

Summary of significant treatment × time effect. حسب Wensheng Xiao (16557866)